MYRIAD GENETICS, INC. (MYGN) Free cash flow 2016–2025
MYRIAD GENETICS, INC. (MYGN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$13.8MFY2025 · since FY2016: $100.1M → -$13.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$13.8M | +50.2% |
| FY2024 | -$27.7M | +84.1% |
| FY2023 | -$174.1M | -14.8% |
| FY2022 | -$151.6M | -25366.7% |
| FY2021 | $600,000 | — |
| FY2019 | $50.5M | -32.8% |
| FY2018 | $75.1M | -30.1% |
| FY2017 | $107.5M | +7.4% |
| FY2016 | $100.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More MYGN financial trends
MYGN RevenueMYGN Net incomeMYGN Net marginMYGN Gross profitMYGN Gross marginMYGN Operating incomeMYGN Operating marginMYGN Operating cash flowMYGN Capital expendituresMYGN Return on equityMYGN Stock buybacksMYGN Dividends paidMYGN Total assetsMYGN Total liabilitiesMYGN Shareholders’ equityMYGN overview →